Professional Documents
Culture Documents
Flupentixol decanoate
(flupenthixol decanoate)
20 mg/mL oily solution in 1-mL and 2-mL ampoules; 1-mL and 2-mL syringes; 10-mL
vials
100 mg/mL oily solution in 0.5-mL and 1-mL ampoules; 5-mL vials
200 mg/mL oily solution in 1-mL ampoules
*
Pre-treatment checks
*
Caution in epilepsy, Parkinson disease, liver disease, renal failure, cardiac disease, depression,
myasthenia gravis, prostatic hypertrophy, narrow-angle glaucoma, hypothyroidism, hyperthyroidism, phaeochromocytoma, severe respiratory disease or if there are risk factors for stroke.
LFTs
Bodyweight
ECG
TFTs
FBC
Dose
Test dose: 20 mg to assess tolerability. Reduce test dose to 5 or 10 mg if patient is elderly.
Maintenance dose: commence at least one week after test dose, usual dose range 50 mg every 4
weeks up to 300 mg every 2 weeks. Some patients may require up to 400 mg weekly.
Intramuscular injection
Preparation and administration
1. Withdraw the required dose. The maximum volume to be administered at one site is 2 mL.
Volumes >2 mL should be distributed between two injection sites.
2. Give by deep IM injection into the upper outer buttock or lateral thigh. Aspirate before injection
to avoid inadvertent intravascular injection. Rotate injection sites for subsequent injections.
Technical information
Incompatible with
Compatible with
Flupentixol decanoate
| 357
Sodium content
Nil
Storage
Monitoring
Measure
Frequency
Rationale
Therapeutic
improvement
Periodically
EPSEs
During dose
adjustment and every
3 months
Renal function
At least annually
LFTs
Blood pressure
Blood glucose
Lipids (including
cholesterol, HDL, LDL
and triglycerides)
Weight and obesity
ECG
Annually
Prolactin
See rationale
Additional information
Common and serious
undesirable effects
Pharmacokinetics
| Folic acid
Action in case of
overdose
Counselling
Score 2
Lower-risk product: Risk-reduction strategies should be considered.
This assessment is based on the full range of preparation and administration options described in the
monograph. These may not all be applicable in some clinical situations.
Bibliography
SPC Depixol (accessed 15 October 2007).
NICE (2009). Clinical Guideline 82: Core interventions in the treatment and management of schizophrenia
in primary and secondary care (update). London: National Institute for Health and Clinical Excellence.
http://guidance.nice.org.uk/CG82 (accessed 1 October 2009).
Folic acid
15 mg/mL solution in 1-mL ampoules
*
It is used to prevent folate deficiency in renal dialysis patients or chronic haemolytic states.